|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Diabetes Mellitus, Type 1 | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Diabetes Mellitus | |||||
| 3 | More general conditions related to this trial | ||||
| Autoimmune Diseases | |||||
| Endocrine System Diseases | |||||
| Glucose Metabolism Disorders | |||||
| Immune System Diseases | |||||
| Metabolic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Antithymocyte globulin | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Antilymphocyte Serum | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||
| Immune Tolerance Network | |||||